Recent 8-K filings for AZTR
Highest-materiality recent filing
Azitra completes IPO of 1.5M shares at $5.00; net proceeds ~$6.5M for clinical development
- Offering of 1.5M shares at $5.00/share; gross proceeds $7.5M, net ~$6.5M after expenses.
- Underwriters have 45-day option to buy up to 225K additional shares for over-allotments.
-
Azitra regains NYSE American compliance; .BC indicator removed
NYSE Regulation letter dated Aug 19, 2026 confirms compliance with all continued listing standards.
-
Azitra Q2 net loss widens to $3.3M; pauses ATR-12, advances ATR-COSF and ATR-04
Net loss $3.3M in Q2 2026 vs $2.9M in Q2 2025; G&A up to $2.1M from $1.5M.
-
Raised $10.5M in March with up to $21M additional from warrant exercises to fund new initiatives.
-
Azitra shareholders approve authorized share increase from 200M to 750M; reverse split authorized
Authorized shares increased from 200M to 750M; Certificate of Amendment filed June 15, 2026.
-
Azitra Q1 net loss $3.9M; adds MD Anderson for ATR-04 trial
Net loss $3.9M ($1.6M R&D, $2.4M G&A); cash $10.1M at March 31, 2026.
-
Azitra raises $10.5M initial PIPE, up to $31.4M with warrants, for cosmetic protein program
Initial gross proceeds of ~$10.5M from sale of Series A preferred & warrants; potential additional ~$20.9M if warrants exercised.
-
Azitra receives second NYSE American non-compliance notice; equity at $3.8M vs $6M minimum
NYSE American notified Azitra of non-compliance with Section 1003(a)(iii) requiring $6M+ equity; as of Dec 31, 2025 equity was $3.8M.
-
Azitra reports FY2025 net loss of $11.0M, cash $2.1M; pipeline advances
Net loss widened to $11.0M in FY2025 from $9.0M in FY2024; R&D $4.8M, G&A $6.2M.
-
Azitra adjourns special meeting on stock issuance due to lack of quorum; reconvenes March 6
Special Meeting convened Feb 6, 2026, adjourned to March 6, 2026 after only ~13% of shares voted vs. required 33 1/3% quorum.
-
Azitra obtains NYSE American plan approval; must meet $4M equity by April 2027
NYSE American accepted Azitra's plan to regain compliance with minimum $4M stockholders' equity requirement.
-
Azitra raises $1.5M in private placement of common stock and warrants at $0.32/unit
Gross proceeds $1.5M from sale of 4,687,500 shares (or pre-funded warrants) and warrants to buy 4,687,500 shares at $0.32.
-
Azitra Q3 net loss widens to $2.8M; cash $1.4M; first patient dosed in ATR-04 Ph1/2 trial
Net loss of $2.8M for Q3 2025, compared to $1.0M in Q3 2024.
-
Azitra receives NYSE American delisting notice for insufficient stockholders' equity
Stockholders' equity of $2.2M as of June 30, 2025, below the $4M minimum required.
-
Azitra modifies equity line with Alumni Capital; new pricing at 90% or 97% discount
Modification Agreement dated Aug 26, 2025 amends $20M purchase agreement from April 24, 2025.
-
Azitra Q2 net loss $2.9M; cash $1.0M; ATR-12 Phase 1b shows safety
Net loss of $2.9M for Q2 2025, up from $2.6M in Q2 2024; R&D spend $1.4M, G&A $1.5M.
-
No severe or serious adverse events in ongoing Phase 1b trial of ATR12-351; application site reactions transient, self-resolving, observed bilaterally.
-
Azitra Q1 net loss $3.1M, cash $3.2M; secures up to $20M funding from Alumni Capital
Net loss $3.1M for Q1 2025 vs $2.9M in Q1 2024; R&D $1.3M, G&A $1.9M.
-
Azitra enters up to $20M equity line with Alumni Capital for clinical pipeline funding
Purchase Agreement with Alumni Capital LP for up to $20M of common stock and warrants over 20 months.
-
Azitra reports FY2024 net loss of $9.0M; cash $4.6M; trial updates for ATR-12 and ATR-04
Net loss $9.0M vs $11.3M in FY2023; R&D expenses $4.7M, G&A $6.3M.
-
Azitra prices $1.5M public offering of 4.86M shares at $0.30/share
Gross proceeds of $1.5M from sale of 4,857,780 shares at $0.30/share; offering closed Jan 16, 2025.
-
Azitra Q3 net loss narrows to $1.0M; pipeline advances with ATR-12 dosing, ATR-04 IND clearance
Net loss of $1.0M in Q3 2024 vs $1.9M in Q3 2023; cash and equivalents $7.3M as of Sept 30, 2024.
-
Azitra closes $10M public offering of 6.67M shares and warrants at $1.50/unit
Gross proceeds ~$10.0M; net proceeds ~$8.95M after placement agent fees and expenses.
-
Azitra stockholders approve 1-for-30 reverse stock split
Reverse split ratio set at 1:30; filed with Delaware Secretary of State on June 27, 2024.
-
Azitra Q1 2024 net loss $2.9M; cash $3.0M; ATR-12/ATR-04 clinical updates
Q1 2024 net loss $2.9M vs $2.5M YoY; R&D and G&A each $1.5M vs $0.8M prior year.
-
Azitra reports FY2023 net loss $11.3M, cash $1.8M; advances ATR-12 Phase 1b and ATR-04 IND
Net loss $11.3M vs $10.7M in 2022; service revenue from related party $0.7M.
-
Azitra prices $5M public offering of 16.7M shares at $0.30/share
Pricing of 16,667,000 shares at $0.30/share for gross proceeds of ~$5M.
-
Azitra completes IPO of 1.5M shares at $5.00; net proceeds ~$6.5M for clinical development
Offering of 1.5M shares at $5.00/share; gross proceeds $7.5M, net ~$6.5M after expenses.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event other_material